Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?

A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR⁺/HER2⁺ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients.

See related article by Shagisultanova et al., p. 5021